MA-CYTOTRONICS
10.7.2024 08:01:25 CEST | Business Wire | Press release
CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, introduced its high-throughput Pixel™ Octo system at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709748131/en/
CytoTronics is launching its high-throughput Pixel™ Octo system (right) at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo (left), a single plate reader that brings accessibility to researchers. (Photo: Business Wire)
This new addition to the Pixel lineup integrates the company’s semiconductor-to-live-cell interface in an environmental controlled benchtop system to deliver live cell measurements for up to eight 96-well Pixel plates simultaneously. When paired with laboratory robotic automation, the Pixel Octo offers full scalability in high-throughput cell biology applications. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo, a single plate reader that brings accessibility to researchers for under US$30,000.
Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, and more while generating electrical ‘images’ with single-cell spatial resolution. It dramatically accelerates the scale at which cell biology applications can be executed, and the breadth and depth of live-cell insights obtained. Pixel enables new applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.
Scale up of in vitro cell-based assays is challenging. Traditionally, these screening assays at high scale use hundreds of 96- or 384- well plates to measure simple cellular properties (e.g., "live or dead" screens) to select the most prospective 'hits' of interest, which are then 'scaled down' to verify key effects on cellular functions. Pixel gives researchers a highly sophisticated tool to start key investigations first, get the functional phenotypic assets they cannot get through imaging and other basic techniques, and easily scale these newly developed assays to high-throughput workflows.
The Pixel plate, a proprietary 96-well electronic microplate embedded with custom-designed semiconductor microchips at the base of each well, is at the core of CytoTronics’ Pixel platform. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, enabling thousands of measurements to be taken per well on a single-cell level, on any cell type, spheroid, or 3D organoid system.
In-vitro cell-based assays can initially be developed on Pixel Primo, a single plate reader that can be placed in any standard cell culture incubator. Cell biologists can then scale those assays 8× on Pixel Octo, a self-contained benchtop system complete with a dedicated incubator to regulate temperature, CO2, humidity, and oxygen. Labs can integrate Pixel Octo with industry standard robotic and liquid handling platforms, and multiple systems can be run in parallel for high-throughput applications. Availability of 384-well Pixel plates later in 2024 raises the scalability bar significantly, adding capability to screen tens of thousands of wells simultaneously.
“There’s a tremendous unmet need in cell biology discovery applications to measure the unique cell parameters that Pixel captures. It unlocks new applications and reveals data that scientists haven’t been able to study before,” said Jeffrey Abbott, Ph.D., Co-Founder and CEO of CytoTronics. “Pixel Octo takes the power of our unique semiconductor-to-biology interface from assay development in a single plate and unleashes it for high-throughput applications, from exploratory assays on a single Pixel plate to fully validated cell-based applications running at industrial scale.”
“Our early access program for the Pixel Primo kicked off in February and already has 20 global partners spanning biotech, pharmaceutical, academic, cell and organoid providers, and computational biology organizations who are very quickly gaining traction on their applications,” said Duane Sword, Co-Founder and CBO at CytoTronics. “Pixel Octo was designed with scalability in mind and provides cell monitoring and data collection at unprecedented scale. Importantly, Pixel is complementary with imaging and HCS (high content screening) techniques and designed to integrate with standard automation workflows. Pixel is rich with information on biology never seen before, let alone at scale. Hence, we have designed the system with a cloud-centric architecture spanning measurement design, execution, analysis and reporting.”
Through the CytoTronics early access program, customers receive a Pixel Primo, 96-well Pixel plates and Pixel Pro, a cloud-based control and interactive analysis software. A starting list price of under $30K (USD) makes it easy for labs to evaluate Pixel as the next frontier of their cell biology research programs.
To learn more about Pixel or enroll in the early access program, visit www.cytotronics.com. You can also visit CytoTronics at ISSCR in Hall H booth #1016 and attend our talks on “Electrical imaging: live cell characterization from stem cell biology to phenotypic disease models”, presented by Shalaka Chitale, CytoTronics’ Director of Biology, Thursday July 11 at 9:10am - 9:20am and Friday July 12 at 6:00pm – 6:30pm.
About Pixel
CytoTronics’ breakthrough semiconductor-to-live-cell interface powered by microchips enables thousands of multi-modal readouts on any cell type or organoid system. Live cell function is monitored on a Pixel plate, a proprietary 96- or 384-well microplate embedded with microchips at the base of each well. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, allowing thousands of measurements to be taken per well. Pixel Primo and Octo offer simultaneous monitoring of cells across all wells of either a single Pixel plate or eight at the same time. Cloud-based Pixel Pro software enables applications across multiple cell types and organoids with cloud-based control and interactive analysis of the data-rich, live cell measurements collected.
About CytoTronics
At CytoTronics, we are transforming cell biology discovery with our high-throughput, semiconductor-based platforms. Our Pixel systems provide live cell insights with single-cell resolution across all cell types. By seamlessly integrating semiconductors with conventional microplates, Pixel unlocks multi-modal electrical, electrochemical, and electrophysiological capabilities, delivering an unprecedented scope of data collection and scale-up for cell biology research, drug development, and pharmaceutical manufacturing applications. Established as a spin-off from Harvard University in 2021, we are headquartered in Boston, Massachusetts. Learn more at www.cytotronics.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709748131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim12.5.2026 19:39:00 CEST | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded. “We respect the Düsseldorf Local Division’s ruling and will continue to make our case that Angel has not violated any valid patents,” said Dr. Arno Riße, Angel’s attorney at the Arnold Ruess law firm of Düsseldorf. “We are grateful that the court decided not to grant Align's request for preliminary measures. Angel takes intellectual property rights seriously and is careful not to infringe on legitimate patents.” “We categorically deny the allegations of i
Bharat Forge Signs Long-Term Contract with Embraer for Landing Gear Forgings12.5.2026 18:38:00 CEST | Press release
Bharat Forge Ltd. (BFL) (BSE: 500493, NSE: BHARATFORG), a global leader in advanced forging and precision engineering, today announced a long-term contract with Embraer for the manufacturing and supply of critical landing gear forgings. With this milestone, Bharat Forge becomes the first Indian supplier to join Embraer’s global aerospace supply chain for forged components. Under the agreement, Bharat Forge will supply high-integrity forged components for landing gear systems across Embraer’s commercial and Defence aircraft programs. This engagement establishes a strategic partnership anchored in advanced manufacturing capabilities, precision engineering, and proven expertise in delivering complex, safety-critical components for global aerospace platforms. The long-term contract reflects a shared commitment to quality, reliability, and sustained collaboration, and reinforces Embraer’s confidence in Bharat Forge’s ability to meet stringent global certification standards while consistentl
De' Longhi Group - 6.6% Growth at Constant Exchange Rates and Accelerated Net Profit: Solid Results Fully Support Guidance12.5.2026 18:37:00 CEST | Press release
The Group closed another quarter with robust organic growth, driven by the excellent expansion of the professional division, with turnover growing significantly and representing 18% of the Group's total for the period, and by the positive performance of the household The Board of Directors of De' Longhi S.p.A. approved the consolidated results 1for the first quarter of 2026: In the first quarter the Group achieved: revenues of € 777.7 million, up 3% (+6.6% at constant exchange rates); adjusted 2Ebitda of € 125.9 million, equal to 16.2% of revenues (15.4% in Q1-25); net profit (pertaining to the Group) of € 61.7 million, equal to 7.9% of revenues and up 7.5% compared to the previous year; net financial position at the end of March 2026 of € 720.5 million. CEO Fabio de' Longhi commented: “The start of 2026 was marked by solid revenue growth of 6.6% at constant exchange rates, continuing the excellent performance achieved in recent years. The professional division's strong expansion susta
Multi-Color Corporation Successfully Completes Comprehensive Financial Restructuring12.5.2026 18:09:00 CEST | Press release
Company Emerges Stronger, Well-Positioned to Execute Long-Term Strategy With Significantly Deleveraged Balance Sheet Multi-Color Corporation ("MCC" or the "Company") today announced the successful completion of the Company’s financial restructuring process and emergence from its prepackaged Chapter 11 process. The Company’s prepackaged restructuring reduced net debt by approximately $3.8 billion, reduced annualized cash interest expense by more than $330 million, and extended long-term debt maturities to 2033. More than 99% of voting stakeholders voted to accept MCC’s Plan of Reorganization. Upon emergence, MCC also received a significant $889 million new common and preferred equity investment from CD&R and a group of MCC’s existing secured lenders to support MCC’s long-term growth and investment. "Today marks a significant milestone for MCC, as well as our customers, teammates, and partners who have supported us throughout this process,” said Hassan Rmaile, President and Chief Executi
New Cessna Caravans to Boost USDA’s Fight Against Crop-Damaging Insects12.5.2026 17:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) has ordered three Cessna Caravan aircraft to support its sterile insect release program protecting citrus crops along the Rio Grande River in southern Texas. The new aircraft are expected to be delivered in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512676348/en/ Mission-Ready: The Cessna Caravan joins USDA’s fight to protect Texas citrus from invasive pests APHIS will use the Caravans to carry and release sterile insects that help prevent the spread of destructive pests, including fruit flies. The environmentally friendly technique helps safeguard fruit-bearing trees, reduce crop damage and protect agricultural industries that rely on healthy harvests. “These aircraft will help APHIS reach remote areas and carry out their important mission o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
